News
BHST
4.160
+3.87%
0.155
BioHarvest Sciences: Buy Rating Reiterated on Strengthening Fundamentals and CDMO Growth, $14 Price Target Reaffirmed
TipRanks · 1h ago
Craig-Hallum Sticks to Their Buy Rating for BioHarvest Sciences (BHST)
TipRanks · 14h ago
BioHarvest Sciences Posts Q1 2026 Growth and Advances Botanical Synthesis Deals
TipRanks · 14h ago
BioHarvest outlines 2026 revenue of $38M-$42M in D2C and $12M-$14M in CDMO activity while targeting 2H 2027 fragrance production
Seeking Alpha · 17h ago
BioHarvest Sciences Files Q1 2026 Financials on Form 6-K
TipRanks · 17h ago
BioHarvest Sciences Names New Business Development Chief to Drive CDMO Growth
TipRanks · 20h ago
BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est
Benzinga · 23h ago
BioHarvest Sciences Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $8.500M Miss $8.796M Estimate
Benzinga · 1d ago
BioHarvest Sciences reports Q1 results
Seeking Alpha · 1d ago
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Newsfile · 1d ago
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Newsfile · 1d ago
BioHarvest Advances Saffron CDMO Program to Stage 2 After Completing Cell Bank Milestone
TipRanks · 1d ago
BioHarvest Sciences' CDMO Division Completes Stage 1 Under Multi-Stage Development Agreement, Establishing Stable Saffron Cell Bank For Potential Nutraceutical And Culinary Applications
Benzinga · 1d ago
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
Newsfile · 1d ago
BioHarvest Sciences Secures $1.2M Stage 2 CDMO Deal for Rare Fragrance Development
TipRanks · 2d ago
BioHarvest Sciences' CDMO Division Signs $1.2M Stage 2 Contract As Part Of Multi-Stage Development Program For Rare Scent-Producing Plant Used In Global Fragrance Industry
Benzinga · 2d ago
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
Newsfile · 2d ago
BioHarvest Sciences Installs Co-Founder Zaki Rakib as CEO in Strategic Leadership Shift
TipRanks · 3d ago
Weekly Report: what happened at BHST last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at BHST last week (0427-0501)?
Weekly Report · 05/04 10:20
More
Webull provides a variety of real-time BHST stock news. You can receive the latest news about Bioharvest through multiple platforms. This information may help you make smarter investment decisions.
About BHST
BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.